Rose McNulty

An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.

TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.

Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.

Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.

Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.

FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.

This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.

A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.

FDA grants lunsotogene parvec-cwha approval for OTOF-related hearing loss, delivering single-dose gene therapy gains and expanding access with free US supply.

The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population.

DELTA 3 trial extension data show sustained improvements in disease-specific, dermatology-specific, and overall quality-of-life measures.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

Nancy L. Lewis, MD, MBS, FACP, discusses her path from the clinic to biopharma and her goals as NCCN's new CSO, including health equity and faster drug development.

Steven Kheloussi, PharmD, explores how smarter clinical tools, multidisciplinary teams, and better care coordination can improve outcomes for people with MS.

Fewer than half of phase 3 chronic spontaneous urticaria (CSU) trials reported baseline disease duration, a review found.

Expert guidance shows how to safely tailor aesthetic dermatology for allergic skin conditions like urticaria and eczema.

Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care delivery.

Icotrokinra is the first and only interleukin-23–targeted oral peptide approved for plaque psoriasis.

Secukinumab becomes the only IL-17A inhibitor approved for this population and the first new mechanism in the indication in nearly a decade.

The mental health burden of vitiligo closely resembles atopic dermatitis but differs significantly from psoriasis, a study suggests.

GPT-4o reliably scored alopecia areata severity from scalp images, showing strong concordance with experienced dermatology providers without prior AI training.

Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and emerging outcome measures.

Recent guideline updates for squamous cell skin cancer add adjuvant cemiplimab as a preferred option for certain patients with very high-risk disease.

ACOs entering MSSP with higher spending were consistently more likely to earn bonuses—a gap that persisted after a 2017 benchmarking policy change.

Elevance Health's Shane Hochradel explains how the company tracks provider satisfaction and uses AI to cut administrative burden.

Study links moderate to severe alopecia areata to higher atopic dermatitis risk, urging routine screening and smarter treatment choices.

The approval, dupilumab's ninth in the US, is supported by the phase 3 LIBERTY-AFRS-AIMS trial.

Kavita Nair, PhD, discusses how clinicians select MS therapies, the role of cost and access, and why policy changes could threaten patient outcomes.

Reform priorities aim to reshape PBM oversight, delink compensation from drug prices, boost transparency, and protect pharmacy access.